With career highlights including the launch of Ivermectin and NuvaRing, along with expertise spanning microbiome therapeutics, M&A, regulatory affairs, and clinical and non-clinical development, it’s no surprise that Bracken Senior Partner Dr. Graham Lumsden is striving to shift our approach to healthcare. Holding a doctorate in veterinary medicine, Graham takes an integrated approach that bridges the various facets of life sciences. He advocates for preventative medicine and strategic partnerships to drive meaningful changes in the biotech and pharmaceutical industries. With years of experience, Dr. Lumsden recognizes that the future of medicine is not just about treatment—it’s about prevention, accessibility, and aligning scientific progress with market needs.
In this episode of Fractals: Life Science Conversations, Graham and host Colin Miller discuss:
- Why accessible medicine is a smart investment for both patients and payers, shifting the cost burden from reactive to proactive care, and revolutionizing healthcare delivery.
- The power of strategic partnerships and mutual benefits, particularly for small biotech companies seeking to launch successful products.
- The innovative "Label As Driver" (LAD) approach that ensures early product development aligns with market demands and long-term goals.
- How go-to-market and commercialization strategies must adapt to regional differences, prioritizing each market’s unmet needs, effective communication, and connecting treatments to the right audience.
Listen to Fractals: Life Science Conversations on your favorite podcast platform, and contact us today to learn more about working with Graham and Bracken’s team of expert consultants.
Click here to read the transcript version of this episode.
